Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

NCT00977431 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Temozolomide
PROCEDURE: Radiotherapy
DRUG: BIBW2992
PROCEDURE: Radiotherapy
DRUG: BIBW2992

Sponsor

Boehringer Ingelheim